Press "Enter" to skip to content

FDA pulls up Aurobindo Pharma for ‘repeated’ failures in CGMP

The FDA recently issued a letter warning the drug- makers unit X1 in Srikakulam district of Andhra Pradesh for deviations from CGMP for API.

Original source: https://health.economictimes.indiatimes.com/news/pharma/fda-pulls-up-aurobindo-pharma-for-repeated-failures-in-cgmp/70060033?utm_source=RSS&utm_medium=ETRSS

Also Read:   J&J bumps up full-year profit view on strength of cancer drugs